General Information of the Protein
Protein ID |
PT00984
|
||||
---|---|---|---|---|---|
Protein Name |
Intermediate conductance calcium-activated potassium channel protein 4
|
||||
Secondarily Protein Name |
IKCa1
KCa3.1
KCa4
Putative Gardos channel
|
||||
Gene Name |
KCNN4
|
||||
Secondarily Gene Name |
IK1
IKCA1
KCA4
SK4
|
||||
Sequence |
MGGDLVLGLGALRRRKRLLEQEKSLAGWALVLAGTGIGLMVLHAEMLWFGGCSWALYLFLVKCTISISTFLLLCLIVAFHAKEVQLFMTDNGLRDWRVALTGRQAAQIVLELVVCGLHPAPVRGPPCVQDLGAPLTSPQPWPGFLGQGEALLSLAMLLRLYLVPRAVLLRSGVLLNASYRSIGALNQVRFRHWFVAKLYMNTHPGRLLLGLTLGLWLTTAWVLSVAERQAVNATGHLSDTLWLIPITFLTIGYGDVVPGTMWGKIVCLCTGVMGVCCTALLVAVVARKLEFNKAEKHVHNFMMDIQYTKEMKESAARVLQEAWMFYKHTRRKESHAARRHQRKLLAAINAFRQVRLKHRKLREQVNSMVDISKMHMILYDLQQNLSSSHRALEKQIDTLAGKLDALTELLSTALGPRQLPEPSQQSK
Show/Hide
|
||||
Organism |
Homo sapiens, Human
|
||||
Protein Classification |
Ion channel
>
Voltage-gated ion channel
>
Potassium channels
>
Calcium-activated potassium channel
|
||||
Function |
Forms a voltage-independent potassium channel that is activated by intracellular calcium (PubMed:26148990). Activation is followed by membrane hyperpolarization which promotes calcium influx. Required for maximal calcium influx and proliferation during the reactivation of naive T-cells (PubMed:17157250, PubMed:18796614). Plays a role in the late stages of EGF-induced macropinocytosis (PubMed:24591580).
Show/Hide
|
||||
Uniprot ID |
Show/Hide
|
||||
Ensembl ID | |||||
HGNC ID | |||||
Subcellular Location |
Cell membrane
|
Map of Molecular Bioactivity Related to the Protein
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000053 , COS-7
Cell Line ID: CL000006 , HEK293
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Calcium-activated potassium channel KCa3.1 (KCNN4) )
Target Type | Clinical trial Target | ||||
---|---|---|---|---|---|
Disease | 2 Target-related Diseases | 2 | |||
1 | Alzheimer disease [ICD-11: 8A20] | ||||
2 | Conjunctival fibrosis [ICD-11: 9A61.3] | ||||
Clinical Trial Drug(s) | 1 Clinical Trial Drug | 1 | |||
1 | ICA-17043 | Phase 2 | |||
Investigative Drug(s) | 1 Investigative Drug | 1 | |||
1 | 1-((2-chlorophenyl)diphenylmethyl)-1H-pyrazole | Investigative |